Treats hallucinations and delusions associated with Parkinson's disease psychosis. Sold as Nuplazid. Every FDA application for this active ingredient: 2 branded and 3 generic. Boxed warning
As of Nov 22, 2026, FDA lists 5 applications for Pimavanserin tartrate (sold as Nuplazid), first approved Apr 29, 2016, with 5 new uses approved and 0 published complete response letters.
| Apr 29, 2016 | NuplazidNDA 207318 · New molecular entity | ACADIA Pharmaceuticals | 12 | Marketed |
| Jun 28, 2018 | NuplazidNDA 210793 · New dosage form | ACADIA Pharmaceuticals | 7 | Marketed |
| Jan 16, 2024 | PimavanserinANDA 214493 | Zydus | 0 | Discontinued |
| Jan 16, 2024 | PimavanserinANDA 214502 | Zydus | 0 | Discontinued |
| Jan 16, 2024 | PimavanserinANDA 214925 | MSN Laboratories | 0 | Discontinued |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Nuplazid | Part D | $727M | +11% | 18,917 |
Of the 12 whose ending is known, 50% met their primary endpoint, 8% missed it and 42% stopped early.
| Psilocybin for Depression in VeteransMajor Depression · VA Office of Research and Development | Phase 2 | Not yet recruiting | Oct 26, 2026 |
| Psilocybin Efficacy With or Without Pimavanserin PretreatmentMood (Psychological Function), Well Being · Johns Hopkins University | Phase 1 / Phase 2 | Recruiting | May 27, 2026 |
| Investigating the Neuropsychological Effects of 5-HT2a AntagonismHealthy · University of Oxford | Not applicable | Recruiting | Jun 15, 2025 |
| Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.Parkinson Disease · University Hospital, Strasbourg, France | — | Not yet recruiting | Jan 1, 2025 |
| Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderMajor Depressive Disorder · Icahn School of Medicine at Mount Sinai | Phase 2 | Recruiting | Sep 19, 2024 |
| Psilocybin Therapy for Depression in Parkinson's DiseaseParkinson Disease, Depression · Joshua Woolley, MD, PhD | Phase 2 | Recruiting | Jun 12, 2024 |
| Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum DisorderAutism Spectrum Disorder · New York State Psychiatric Institute | Phase 2 | Recruiting | Aug 21, 2023 |
| Pimavanserin and Aggression and Social Cognition.Intermittent Explosive Disorder · Ohio State University | Phase 2 | Recruiting | Jun 8, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA